Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Old and New Biological Therapies for Psoriasis
Kirsten Rønholt, Lars Iversen
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 11, pp. 2297-2297
Open Access | Times Cited: 218

Showing 1-25 of 218 citing articles:

Comparison of Biologics and Oral Treatments for Plaque Psoriasis
April W. Armstrong, L. Puig, Avani Joshi, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 3, pp. 258-258
Open Access | Times Cited: 218
An update on generalized pustular psoriasis
Melinda Gooderham, Abby S. Van Voorhees, Mark Lebwohl
Expert Review of Clinical Immunology (2019) Vol. 15, Iss. 9, pp. 907-919
Open Access | Times Cited: 195
Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis
Sofie Vaengebjerg, Lone Skov, Alexander Egeberg, et al.
JAMA Dermatology (2020) Vol. 156, Iss. 4, pp. 421-421
Open Access | Times Cited: 174
Psoriasis and Treatment: Past, Present and Future Aspects
Claire Reid, C.E.M. Griffiths
Acta Dermato Venereologica (2020) Vol. 100, Iss. 3, pp. 70-80
Open Access | Times Cited: 164
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Rohan Singh, Sindhuja Koppu, Patrick O. Perche, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12793-12793
Open Access | Times Cited: 110
Current Concepts of Psoriasis Immunopathogenesis
Marijana Vičić, Marija Kaštelan, Ines Brajac, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11574-11574
Open Access | Times Cited: 106
Polymeric Nanoparticles as Tunable Nanocarriers for Targeted Delivery of Drugs to Skin Tissues for Treatment of Topical Skin Diseases
Eiman Abdalla Madawi, Alaa Raad Al Jayoush, Mutasem Rawas‐Qalaji, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 657-657
Open Access | Times Cited: 56
Extra-adrenal glucocorticoid biosynthesis: implications for autoimmune and inflammatory disorders
Radomir M. Slominski, Robert C. Tuckey, Pulak R. Manna, et al.
Genes and Immunity (2020) Vol. 21, Iss. 3, pp. 150-168
Open Access | Times Cited: 123
Emerging landscape in psoriasis management: From topical application to targeting biomolecules
Vamshi Krishna Rapalli, Gautam Singhvi, Sunil Kumar Dubey, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 106, pp. 707-713
Closed Access | Times Cited: 90
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
Akshitha Thatiparthi, Amylee Martin, Jeffrey Liu, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 4, pp. 425-442
Open Access | Times Cited: 85
Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
Anja St Clair-Jones, Francesca Prignano, João Gonçalves, et al.
Rheumatology and Therapy (2020) Vol. 7, Iss. 4, pp. 741-757
Open Access | Times Cited: 77
Psoriasis: pathological mechanisms, current pharmacological therapies, and emerging drug delivery systems
Vamshi Krishna Rapalli, Tejashree Waghule, Srividya Gorantla, et al.
Drug Discovery Today (2020) Vol. 25, Iss. 12, pp. 2212-2226
Closed Access | Times Cited: 75
Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis
Juliana Santos Rosa Viegas, Fabíola Silva Garcia Praça, Angelo Luis Caron, et al.
Drug Delivery and Translational Research (2020) Vol. 10, Iss. 3, pp. 646-660
Closed Access | Times Cited: 71
Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
Yamin Shu, Yufeng Ding, Yanxin Liu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 66
Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics
Hakim Ben Abdallah, Claus Johansen, Lars Iversen
Psoriasis Targets and Therapy (2021) Vol. Volume 11, pp. 83-97
Open Access | Times Cited: 58
Relationship between Immune Cells, Depression, Stress, and Psoriasis: Could the Use of Natural Products Be Helpful?
Alessio Alesci, Eugenia Rita Lauriano, Angelo Fumia, et al.
Molecules (2022) Vol. 27, Iss. 6, pp. 1953-1953
Open Access | Times Cited: 47
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
April W. Armstrong, Kyle Fahrbach, Craig L. Leonardi, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 8, pp. 1777-1792
Open Access | Times Cited: 41
A bibliometrics study on the status quo and hot topics of pathogenesis of psoriasis based on Web of Science
Yujie Yang, Xuwei Zheng, Haiying Lv, et al.
Skin Research and Technology (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 13
A complex molecular landscape to drug delivery concept for achieving precise therapy in psoriasis
Krishna Yadav, Kantrol Kumar Sahu, Sucheta, et al.
Medicine in Drug Discovery (2024) Vol. 22, pp. 100183-100183
Open Access | Times Cited: 13
Advances in Targeted Therapies for Rehumatiod Arthritis: From Biologic to Small Molecule Inhibitors
Wasia Mansoor, Syed Moin Hassan, Aziz Ur Rahman, et al.
Indus journal of bioscience research. (2025) Vol. 3, Iss. 3, pp. 76-88
Closed Access | Times Cited: 1
Safety of selective IL ‐23p19 inhibitors for the treatment of psoriasis
Jeffrey Crowley, Richard B. Warren, Jennifer Cather
Journal of the European Academy of Dermatology and Venereology (2019) Vol. 33, Iss. 9, pp. 1676-1684
Open Access | Times Cited: 72
Murine models of psoriasis and their usefulness for drug discovery
Shih-Yi Chuang, Chih-Hung Lin, Calvin T. Sung, et al.
Expert Opinion on Drug Discovery (2018) Vol. 13, Iss. 6, pp. 551-562
Closed Access | Times Cited: 68
Th1, Th17, and Treg Responses are Differently Modulated by TNF-α Inhibitors and Methotrexate in Psoriasis Patients
Sandro C. Furiati, Jonatas da Silva Catarino, Marcos Silva, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 68
Luteolin attenuates imiquimod–induced psoriasis-like skin lesions in BALB/c mice via suppression of inflammation response
Wei Zhou, Hu Mengmeng, Xiaohao Zang, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 131, pp. 110696-110696
Open Access | Times Cited: 56
Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis
Viktor Todorović, Zhi Su, C. Brent Putman, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 55
Page 1 - Next Page

Scroll to top